PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Merrimack Pharmaceuticals, Inc. (MACK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US5903282094

CUSIP

590328209

Sector

Healthcare

IPO Date

Mar 29, 2012

Highlights

Market Cap

$223.75M

EPS (TTM)

-$0.09

PEG Ratio

0.07

EBITDA (TTM)

-$669.00K

Year Range

$14.60 - $15.17

Target Price

$4.00

Short %

8.25%

Short Ratio

8.65

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Merrimack Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


MACK (Merrimack Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Returns By Period


MACK

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

4.22%

1M

2.22%

6M

9.51%

1Y

22.46%

5Y*

12.74%

10Y*

11.29%

*Annualized

Monthly Returns

The table below presents the monthly returns of MACK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-0.07%9.70%0.48%-0.20%12.83%
20231.13%-0.95%7.06%0.98%0.89%-1.76%-2.36%1.67%0.98%-0.81%3.19%6.26%17.02%
202232.48%20.46%1.36%-8.30%-10.69%14.86%-14.45%-18.47%-9.64%0.53%215.92%-3.78%193.09%
2021-2.47%-3.57%-3.09%12.26%-9.22%-0.16%-12.36%-10.36%-3.78%-10.97%-2.33%-6.90%-43.25%
2020-2.54%-5.86%-25.61%71.63%-8.13%-1.77%-0.30%24.40%-3.15%-3.50%1.55%75.77%118.73%
201943.78%10.09%13.75%-5.90%-10.40%3.24%1.49%2.12%-8.71%-12.22%-8.35%-2.14%16.73%
20182.44%5.81%-27.54%5.34%3.42%-44.01%5.30%14.51%-9.96%-27.02%12.34%-11.67%-62.34%
2017-23.77%-1.29%0.33%8.12%-1.59%-31.68%7.26%2.26%6.91%-19.26%-1.53%-11.33%-54.64%
2016-21.90%-6.16%44.56%-15.41%-5.79%-19.19%7.61%-20.34%37.45%-17.80%5.56%-25.95%-48.35%
2015-16.55%13.68%10.82%-6.57%6.31%4.79%-18.32%-0.10%-15.66%9.75%0.75%-16.05%-30.09%
2014-1.52%-5.14%1.20%-12.90%76.99%-6.18%-18.93%18.11%25.79%4.44%-0.11%23.36%111.97%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 78, MACK is among the top 22% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of MACK is 7878
Overall Rank
The Sharpe Ratio Rank of MACK is 8383
Sharpe Ratio Rank
The Sortino Ratio Rank of MACK is 8383
Sortino Ratio Rank
The Omega Ratio Rank of MACK is 8282
Omega Ratio Rank
The Calmar Ratio Rank of MACK is 6060
Calmar Ratio Rank
The Martin Ratio Rank of MACK is 8484
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Merrimack Pharmaceuticals, Inc. (MACK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
No data
MACK
^GSPC

There is not enough data available to calculate the Sharpe ratio for Merrimack Pharmaceuticals, Inc.. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio
MACK (Merrimack Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History

Merrimack Pharmaceuticals, Inc. provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.


0.00%20.00%40.00%60.00%80.00%100.00%$0.00$2.00$4.00$6.00$8.00$10.002017201820192020202120222023
Dividends
Dividend Yield
PeriodTTM2023202220212020201920182017
Dividend$0.00$0.00$0.00$0.00$0.00$2.00$0.00$10.55

Dividend yield

0.00%0.00%0.00%0.00%0.00%63.41%0.00%102.95%

Monthly Dividends

The table displays the monthly dividend distributions for Merrimack Pharmaceuticals, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024$0.00$0.00$0.00$0.00$0.00$0.00
2023$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2022$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2021$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2020$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2019$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$1.50$0.00$0.00$0.50$2.00
2018$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2017$10.55$0.00$0.00$0.00$0.00$0.00$0.00$0.00$10.55

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


MACK (Merrimack Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Merrimack Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Merrimack Pharmaceuticals, Inc. was 96.92%, occurring on Mar 20, 2020. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-96.92%Apr 24, 20151236Mar 20, 2020
-81.19%Sep 25, 2012281Nov 6, 2013282Dec 19, 2014563
-34.6%Apr 20, 201232Jun 5, 201235Jul 25, 201267
-25.91%Jan 9, 201518Feb 4, 201520Mar 5, 201538
-16.57%Jul 26, 201220Aug 22, 201219Sep 19, 201239

Volatility

Volatility Chart

The current Merrimack Pharmaceuticals, Inc. volatility is 1.70%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


MACK (Merrimack Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Merrimack Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Merrimack Pharmaceuticals, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab